Ajanta Pharma
Ajanta Pharma is an Indian multinational pharmaceutical company specializing in branded generics and finished formulations for specialty therapies and international markets.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Ajanta Pharma Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Established in 1973, the company develops, manufactures and commercializes finished pharmaceutical formulations rather than concentrating primarily on the sale of bulk active pharmaceutical ingredients. Its business includes prescription medicines and branded generics supplied in dosage forms such as tablets, capsules, injectables and ophthalmic preparations. The company’s Indian business is organized around a selected group of specialty and relatively high-growth therapeutic areas. Publicly identified focus areas include ophthalmology, dermatology, cardiology and pain management. This focused approach differs from a broad, mass-market portfolio model: Ajanta Pharma generally seeks to build depth in selected specialties through product development, physician-oriented promotion, regulatory registrations and branded-generic commercialization. The precise brands and indications differ by market and can change as products receive approvals or reach the end of their commercial lives. Ajanta Pharma also has a substantial international orientation. It operates in India and the United States and sells products in more than 30 countries across Africa, Southeast Asia, West Asia and the Commonwealth of Independent States. In many African and Asian markets, its portfolio is broader than the Indian specialty focus and includes antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology and pain-management products. The company has reported more than 1,400 products registered in different countries, with a comparable number under regulatory approval at the referenced point in time. These figures are time-sensitive and should not be treated as current without checking company disclosures. The United States business has been developed around a selective portfolio, including products involving niche or complex technologies. The referenced company profile reported 27 products in the US market at that time. Its international model therefore combines branded generics in emerging markets with a more selective regulatory and product strategy in the United States. Manufacturing is an important part of the company’s operating structure. Ajanta Pharma operates seven manufacturing facilities in India. Six are described as finished-formulation facilities, including sites at Dahej and Paithan approved by the US Food and Drug Administration, while the Guwahati facility serves domestic and emerging markets. Another facility manufactures active pharmaceutical ingredients, primarily for captive use. Manufacturing, product registration and regional distribution together support the company’s geographically diversified formulation business. Ajanta Pharma’s history also includes overseas joint ventures, particularly in Central Asia. In 2003, a joint venture with Turkmenistan’s Ministry of Health was reported to supply approximately half of that country’s pharmaceutical requirements. The company also entered joint ventures involving regional governments in Uzbekistan, Kazakhstan, Kyrgyzstan and Tajikistan. These arrangements were discontinued during the 2010s after proving insufficiently profitable. The company has been listed on Indian stock exchanges and was reported as included in the BSE 500 in 2015 and the S&P BSE 200 by 2019. Its current product mix, leadership, market coverage, manufacturing footprint and financial results should be confirmed through its latest annual reports, exchange filings and official communications.
History
Ajanta Pharma was established in 1973 in India and developed into a multinational pharmaceutical company centered on finished formulations. Over time, its activities came to include research and development, manufacturing, regulatory registration, marketing and distribution of branded generic medicines. Its portfolio has covered both specialty therapies and a wider range of products for international markets. The company’s Indian strategy has emphasized selected specialty areas rather than an undifferentiated product range. Ophthalmology, dermatology, cardiology and pain management have been identified as important domestic focus areas. In overseas markets, particularly across Africa and Asia, Ajanta Pharma has marketed a broader selection of medicines, including antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology and pain-management products. International expansion was especially visible in Southeast Asia and Central Asia. In the early 2000s, Ajanta Pharma was identified as an important contributor to foreign-exchange earnings through Southeast Asian sales. In 2003, a joint venture involving the company and Turkmenistan’s Ministry of Health was reported to supply approximately half of Turkmenistan’s pharmaceutical requirements. The company also formed joint ventures with regional governments in Uzbekistan, Kazakhstan, Kyrgyzstan and Tajikistan. Those ventures were later discontinued during the 2010s because they were not sufficiently profitable. The company’s financial and corporate history has included periods of both strong sales and investment-related pressure. In 2005, it reported a significant loss attributed to a decline in the value of investments. The same historical account reported sales of ₹13.56 billion for that year, described at the time as the highest among Indian pharmaceutical companies. Because this is a historical figure and the underlying accounting context is not reproduced here, it should be interpreted only with reference to the contemporary source and company filings. Ajanta Pharma subsequently strengthened its position as a listed Indian pharmaceutical company. Its stock performance over the four years preceding 2015 was described as having appreciated significantly, and the company was reported as included in the BSE 500 in 2015. By 2019, it was reported as part of the S&P BSE 200 index. Manufacturing has remained central to the company’s model. The referenced profile described seven Indian manufacturing facilities: six for finished formulations and one for active pharmaceutical ingredients, with the API output primarily used internally. The Dahej and Paithan finished-formulation plants were described as US FDA approved, while the Guwahati plant served Indian and emerging markets. In the United States, Ajanta Pharma has pursued a selective market-entry strategy based on niche and complex products. Its broader international business has continued to rely on product registrations, local commercialization and distribution across more than 30 countries. The exact number of products, approvals, facilities and markets changes over time and requires verification against current company disclosures. The company also faced a significant patent dispute in India. Bayer brought proceedings before the Delhi High Court concerning vardenafil and vardenafil hydrochloride. Ajanta argued that Bayer was not using the patent in India for India’s benefit. In January 2017, the court provided partial relief from an injunction, allowing manufacture but restricting sale. After mediation was ordered in February 2017, the parties reached an agreement, although the terms were not publicly specified in the cited account.
- 2019
Reported inclusion in the S&P BSE 200
[1]Ajanta Pharma was reported as listed in the S&P BSE 200 index by 2019.
- 2017
Delhi High Court provides partial relief in Bayer patent case
[1]The court allowed Ajanta Pharma to manufacture the disputed vardenafil product while restricting its sale, before the parties later reached an agreement following mediation.
- 2015
Reported inclusion in the BSE 500
[1]Ajanta Pharma was reported as included in the BSE 500 after a period of substantial stock-price appreciation.
- 2005
Investment-related loss reported
[1]The company reported a significant loss associated with a decline in the value of its investments. The same historical account reported sales of ₹13.56 billion for the year.
- 2003
Turkmenistan joint venture supplies pharmaceuticals
[1]A joint venture between Ajanta Pharma and Turkmenistan’s Ministry of Health was reported to supply approximately half of the country’s pharmaceutical requirements.
- 1973
Company established
[1]Ajanta Pharma was established in India and later developed into a multinational company focused on pharmaceutical formulations.
Products and positioning
A specialty-focused branded-generics and finished-formulations company serving India and a broad group of emerging international markets, with a selective presence in the United States.
Prescription pharmaceuticals
Branded generic medicines
Branded generics are the company’s central commercial category. Ajanta Pharma develops and markets finished prescription medicines under product brands, using therapeutic specialization, regulatory registrations and local commercialization networks. The precise brands and indications vary by country and over time.
Ophthalmology
Ophthalmic products
Ophthalmology is one of Ajanta Pharma’s principal Indian specialty areas. The portfolio includes ophthalmic formulations such as eye drops, with products and approved indications determined by the regulatory status and commercial strategy of each market.
Cardiology
Cardiovascular medicines
Cardiovascular medicines form part of the company’s specialty portfolio in India and its broader international formulation business. Products are marketed as branded generic prescription treatments, with the range differing across national registrations.
Dermatology
Dermatology medicines
Dermatology is a reported high-growth specialty focus in India. Ajanta Pharma supplies finished formulations for dermatological treatment, while individual products, dosage forms and indications vary according to market approvals.
Pain management
Pain-management medicines
Pain management is among the therapeutic areas identified in the company’s Indian business. The category is served through branded generic finished medicines and is also represented in the company’s broader international portfolios.
International branded generics
International therapeutic portfolio
In Africa, Asia and other international regions, Ajanta Pharma markets a wider portfolio spanning antimalarial, gastrointestinal, antibiotic, antihistamine, multivitamin and gynecology products in addition to cardiovascular, dermatology and pain medicines.
Pharmaceutical ingredients
Active pharmaceutical ingredients
The company operates an Indian facility producing active pharmaceutical ingredients, primarily for captive consumption. API manufacturing supports internal formulation operations rather than representing the main public positioning of the brand.
Brand decisions
2017
Response to Bayer vardenafil patent litigationOtherBackground
Bayer alleged that Ajanta Pharma infringed patents covering vardenafil and vardenafil hydrochloride in India.
Action taken
Ajanta challenged the restrictions by arguing that Bayer was not working the patent in India for India’s benefit. The Delhi High Court granted partial relief from an injunction, permitting manufacture but not sale, and later ordered mediation.
Aftermath
Bayer and Ajanta subsequently reached an agreement after mediation was ordered. The cited account does not disclose the settlement terms.
2003
Central Asian government joint-venture strategyM&ABackground
Ajanta Pharma pursued joint ventures with public-sector or regional-government partners in Turkmenistan, Uzbekistan, Kazakhstan, Kyrgyzstan and Tajikistan as part of its international expansion.
Action taken
The company established or participated in regional pharmaceutical ventures, including a Turkmenistan arrangement reported to supply about half of that country’s pharmaceutical requirements.
Aftermath
The Central Asian ventures were discontinued during the 2010s after being judged insufficiently profitable.
Recent events
- 2017
Bayer patent litigation over vardenafil products reaches mediated settlement[1]
Lawsuit
Bayer sued Ajanta Pharma in the Delhi High Court over alleged patent infringement involving vardenafil and vardenafil hydrochloride. In January 2017, the court granted partial relief from an injunction, permitting manufacture but not sale, and mediation was ordered in February. The parties subsequently reached an agreement whose terms were not disclosed.
Ajanta Pharma expands selective United States product portfolio[1]
Product launch
The company’s United States strategy was described as focusing on a selective group of niche and complex-technology products. The referenced profile reported 27 products in the US market at the time of publication.
Ajanta Pharma maintains international formulation expansion[1]
Other
Ajanta Pharma was reported to have products registered across more than 30 countries in Africa, Asia, West Asia and the Commonwealth of Independent States, with a substantial additional pipeline under approval.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ajanta-pharma · Editorial policy · How profiles are compiled